Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

NCT00542009 · View on ClinicalTrials.gov ↗

Study Summary

Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes

Interventions

  • DRUG Placebo
  • DRUG CE-326,597 100 mg QD
  • DRUG CE-326,597 50 mg QD
  • DRUG CE-326,597 25 mg QD
  • DRUG CE-326,597 5mg QD

Study Locations (20)

California

  • Pfizer Investigational Site — Fresno
  • Pfizer Investigational Site — National City
  • Pfizer Investigational Site — San Diego

Florida

  • Pfizer Investigational Site — Miami
  • Pfizer Investigational Site — Ocala
  • Pfizer Investigational Site — West Palm Beach

Georgia

  • Pfizer Investigational Site — Atlanta
  • Pfizer Investigational Site — Conyers

Illinois

  • Pfizer Investigational Site — Chicago
  • Pfizer Investigational Site — Chicago

Minnesota

  • Pfizer Investigational Site — Chaska
  • Pfizer Investigational Site — Minneapolis

Nevada

  • Pfizer Investigational Site — Henderson
  • Pfizer Investigational Site — Las Vegas

Arizona

  • Pfizer Investigational Site — Phoenix

Hawaii

  • Pfizer Investigational Site — Honolulu

Trial Details

FieldValue
Enrollment Target 252 participants
Start Date 2007-12
Est. Completion 2008-11
Phase Phase 2

Sponsor

Pfizer

769 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00542009

The ClinicalTrials.gov registry entry for NCT00542009 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Weight Management appearing as the primary indexed condition, and to 5 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00542009 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00542009 about?

NCT00542009 is a clinical study titled "A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight". Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes

What is the current status of trial NCT00542009?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2007-12. Estimated completion is 2008-11.

What conditions does trial NCT00542009 study?

This clinical trial studies the following conditions: Weight Management, Treatment Of Obesity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00542009?

The interventions under investigation include: Placebo (DRUG), CE-326,597 100 mg QD (DRUG), CE-326,597 50 mg QD (DRUG), CE-326,597 25 mg QD (DRUG), CE-326,597 5mg QD (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00542009?

This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00542009 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial